Product Search for novus: Novus Biologicals

NBP2-24729

TLR9 Antibody (26C593.2) - BSA Free

(4 Reviews)

(152 Publications)

0.1 mg

NBP2-24729

<b>Genetic Strategies Validation. </b>Knockdown Validated: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR-9 protein in HB cells before and after 48 hr of transfection. Beta-actin was used as an internal control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092748) licensed under a CC-BY license.

Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of colonic LP or peritoneal cavity (PerC) of normal mice were evaluated by flow cytometry. B cells were intracellularly stained with the anti-TLR9 antibody after the cell surface staining with anti-B220 and CD5 antibodies, and examined using flow cytometry. N = 3, performed twice. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0146191) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: TLR9 Antibody (26C593.2) [NBP2-24729] - Cbl-b is required for the endocytic transit of TLR9. Representative confocal microscopic images of splenocytes from mice with indicated genotypes. For experiments, cells were stimulated through the BCR (green) for 30 minutes then fixed and stained for TLR9 (blue) and Lamp-1 (red)(n = 3). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0089792) licensed under a CC-BY license.

Immunohistochemistry-Paraffin: TLR9 Antibody (26C593.2) [NBP2-24729] - Monkey retina tissue. Image from verified customer review.

Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Gating strategy for the detection of TLR-7 and -9 in B cell subsets. PBMC were isolated from whole blood and stained for surface markers before cells were fixed, permeabilised and stained for TLR-9. FSC and SSC were first used to gate out debris and SSC-A and SSC-H was utilized to eliminate duplicates. Further gating was done on CD45 and CD19, to target B cells. To separate between the different B cell populations, we gated on CD27 and IgD (D), followed by TLR-9 expression on these subsets. Data from one representative patient is shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0120383) licensed under a CC-BY license.

Western Blot: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of TLR9 in A) human PBMC, B) human intestine, C) mouse intestine, and D) rat intestine tissue lysates using this antibody at a dilution of 3 ug/ml.

Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR9 on turbinate epithelial cells from healthy controls compared to turbinate and polyp epithelial cells from patients with CRSwNP, n = 5 (A). Intracellular staining for TLR9 (open histogram, black line) and isotype control (filled histogram) on turbinate epithelial cells from a healthy control (B), turbinate epithelial cells (C) and polyp epithelial cells from a patient (D), analysed using flow cytometry. Results are presented as mean +/- SEM, **P<0.01. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0105618) licensed under a CC-BY license.

TLR9 activation upregulated PD-L1 expression by promoting STAT3 Tyr705 phosphorylation in HCC cells. (A) PD-L1 protein expression after treatment with ODN2216 with different concentrations or the indicated times (different concentrations: 0, 5, 10, or 20uM; times: 0, 6, 12, 24, and 36 hours in 10 uM) in Hep3B cells. PD-L1 protein levels were analyzed by Western blotting. (B) PD-L1 protein expression after treatment with ODN2216 with different concentrations or the indicated times (different concentrations: 0, 2.5, 5, or 10uM; times: 0, 6, 12, 24, and 36 hours in 10 uM) in Huh7 cells. PD-L1 protein levels were analyzed by Western blotting. (C) PD-L1 protein expression after treatment with ODN1585 with different concentrations or the indicated times (different concentrations: 0, 2.5, 5, and 10 uM; times: 0, 6, 12, 24, and 36 hours in 5uM) in Hepa1-6 cells. PD-L1 protein levels were analyzed by Western blotting. (D) PD-L1+ tumor cells were detected by flow cytometry after TLR9 agonist (Hep3B and Huh7 cells with ODN2216; Hepa1-6 cells with ODN1585) treatment with indicated concentration. (values are mean +/- SD, *p < 0.05, **p < 0.01, ***p<0.001, NS indicates no significance). (E) PD-L1 expression after TLR9 overexpression in Huh7 cells. PD-L1 expression levels were analyzed by immunofluorescence. (F) PD-L1 protein expression after TLR9 overexpression in Huh7 cells. PD-L1 protein levels were analyzed by Western blotting. (G) PD-L1 protein expression in TLR9 knockdown or TLR9 rescue Hep3B cells. PD-L1 protein levels were analyzed by Western blotting. (H and I) mRNA levels of PD-L1 in Hep3B (H) and Huh7 (I) cells measured by qRT-PCR after stimulation with different concentrations of ODN2216. (values are mean +/- SD, *p < 0.05, **p < 0.01, NS indicates no significance) (J) TLR9 overexpression-induced PD-L1 expression after MYC, JUN, IRF1, IRF3, STAT1 or STAT3 silencing. PD-L1 mRNA expression in Huh7 cells was analyzed after TLR9 overexpression alone or in the presence of MYC-, JUN-, IRF1-, IRF3-, STAT1- or STAT3-specific siRNA or siRNA-NC. (values are mean +/- SD, ***p<0.001). (K) p-STAT3 (Tyr705) levels in Hep3B cells after treatment with different concentrations of ODN2216 (a TLR9 agonist; ODN2216: 0, 2.5, 5, or 10uM) analyzed by Western blotting. (L) p-STAT3 (Tyr705) levels after TLR9 overexpression in Huh7 cells analyzed by Western blotting. (M) TLR9 overexpression-induced p-STAT3 (Tyr705) levels after TLR9 inhibition. p-STAT3 (Tyr705) levels were analyzed after TLR9 overexpression alone or in the presence of the TLR9 antagonist chloroquine diphosphate. (N) p-STAT3-induced PD-L1 levels after STAT3 inhibition. PD-L1 levels were analyzed after TLR9 overexpression alone or in the presence of the STAT3-specific small molecular inhibitor BP-1-102. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32483468), licensed under a CC-BY licence.

Reactivity:

Hu, Mu, Rt, Ca, Eq, Pm, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Ca, Eq, Pm, Pm

Applications:

, , , , , , , , , , ,

Applications: , , , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-305A

Alt Catalog# IMG-305A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24729AF350
Alexa Fluor 405	NBP2-24729AF405
Alexa Fluor 488	NBP2-24729AF488
Alexa Fluor 532	NBP2-24729AF532
Alexa Fluor 594	NBP2-24729AF594
Alexa Fluor 647	NBP2-24729AF647
Alexa Fluor 700	NBP2-24729AF700
Alexa Fluor 750	NBP2-24729AF750
Allophycocyanin	NBP2-24729APC
Biotin	NBP2-24729B
Biotin	NBP2-24890
DyLight 350	NBP2-24729UV
DyLight 405	NBP2-24729V
DyLight 488	NBP2-24729G
DyLight 550	NBP2-24729R
DyLight 594	NBP2-24729DL594
DyLight 650	NBP2-24729C
DyLight 680	NBP2-24729FR
DyLight 755	NBP2-24729IR
FITC	NBP2-24729F
HRP	NBP2-24729H
Janelia Fluor 549	NBP2-24729JF549
Janelia Fluor 646	NBP2-24729JF646
PE	NBP2-24907
PE	NBP2-24729PE
PerCP	NBP2-24729PCP
mFluor Violet 450 SE	NBP2-24729MFV450
mFluor Violet 500 SE	NBP2-24729MFV500
mFluor Violet 610 SE	NBP2-24729MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-24863
BSA Free	NBP2-24729SS

compare

(select up to 3 products from this page to compare)

NB100-56566

TLR4 Antibody (76B357.1) - BSA Free

(5 Reviews)

(138 Publications)

0.1 mg

NB100-56566

Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. Double-stained immunofluorescence for TLR4 (green) and vimentin (red) in normal (I), adenoma (II), and colon adenocarcinoma (III) (10x). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.

Western Blot: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using 2 ug/mL on (A) human intestine and 6 ug/mL on (B) mouse intestine and (C) rat intestine lysate.

Flow (Intracellular): TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using PE conjugate of NBP2-27149. An intracellular stain was performed on Jurkat cells with TLR4 antibody (76B357.1) NBP2-27149PE (blue) and an isotype control MAB004 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.

Immunocytochemistry/Immunofluorescence: TLR4 Antibody (76B357.1) [NB100-56566] - RH-30 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-TLR4 Antibody (76B357.1) NB100-56566 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Immunofluorescent staining of TMAs. Representative tissue cores from normal (I), adenomatous polyps (II), and CRC (III and IV) are shown. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of rat salivary gland tissue section at 1:100 dilution. The antibody generated a membrane-cytoplasmic staining in the tissue with stronger signal in ductal epithelial cells.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Tissue section of normal human skin stained with antibody at 5 ug/mL. Membrane-cytoplasmic immunopositivity of TLR4 was primarily observed in the pigmented basel cells and the adjacent keratinocytes in the epidermal layer.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on RH30 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human skin stained with at 5 ug/mL, peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of TLR4 in FFPE human colon tissue using an isotype control (top) and NB100-56566 (bottom) at 5 ug/mL.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human testis tissue stained with antibody at 5 ug/mL.

Immunohistochemistry-Frozen: TLR4 Antibody (76B357.1) [NB100-56566] - This image is TLR4(green) and nucleus(blue) at area postrema of the adult male mouse brain, x20 magnification. Primary antibody diluted 1:500. IHC-Fr image submitted by a verified customer review.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of formaldehyde fixed THP-1 cells (human monocytic leukemia cells) using 2 ug/10^6 cells TLR4 antibody (clone 76B357.1) with detection employing a donkey anti-mouse IgG (H+L) cross adsorbed secondary antibody, (DyLight 488 conjugated). Isotype control samples incubated with mouse IgG2b isotype control antibody were processed in parallal under the same assay conditions.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Jurkat cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Raw264.7 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Representative images of immunohistochemical staining of pancreatic adenocarcinoma upregulated factor (PAUF) and toll-like receptor 4 (TLR4) in human ovarian cancer specimens. The top row (A,B) represents normal ovarian tissue, middle row (C,D) shows immunoreactivity of ovarian carcinomas and the bottom row (E,F) indicates immunonegativity of ovarian caricinoma. The stromal cells of normal ovarian tissue show immunonegativity for PAUF and TLR4. The scale bar represents 100 μm.

ALWPs significantly reduced LPS-induced cell-surface levels of TLR4. (C) BV2 microglial cells were pretreated with ALWPs (500 ug/ml) or PBS for 30 min, followed by treatment with LPS (1 ug/ml) or PBS for 5.5 h. Cell-surface biotinylation was then conducted with a TLR4 antibody recognizing the N-terminal region of TLR4. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30319390), licensed under a CC-BY licence.

Effect of Cucumis sativus L. extract (CSE) on LPS induced TLR4 expression. b) Representative Western Blot of TLR4 and relative housekeeping alpha-tubulin were reported. c Expression of TLR4 protein in pAECs treated with LPS (10 ug/ml) in the presence or absence of increasing doses CSE (0.02; 0.2; 2 mg/ml); data shown are representative of at least three independent experiments and represent the mean +/- SEM. Different letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey's test) Image collected and cropped by CiteAb from the following publication (//bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-018-2254-1), licensed under a CC-BY licence.

Dasatinib affects TLR4 signaling to regulate LPS-induced proinflammatory cytokine levels in BV2 microglial cells. d) BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 ug/ml) or PBS for 5.5 h, and cell surface biotinylation was conducted. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31655606), licensed under a CC-BY licence.

Corroboration of human AKR2–protein interactions with highest confidence. (A) Representation of the components of the protein pull-down experiment using c-Myc magnetic beads with Myc-tagged human AKR2. (B) Western blot analysis of AKR2–protein interactions. Interacting proteins were incubated with AKR2 and immunopresipitated with c-Myc magnetic beads specific for the AKR2 protein tag (I) or with the c-Myc magnetic beads only as negative control (C-). Recombinant interacting proteins were included as positive control (C+). Mouse or rabbit antibodies specific for each protein were used as primary antibodies and then anti-mouse or anti-rabbit secondary antibodies were used to identify the presence of the interacting proteins (red arrow). The origin of the primary antibody is shown. (C) Corroboration of human AKR2–AKR2 interaction using protein pull-down with c-Myc magnetic beads with human Myc-tagged AKR2. The experiment was conducted as described in (B). The origin of the primary antibody and predicted size for AKR2 monomer, dimer, and trimer together with bands corresponding to fragments of the mouse anti-c-Myc antibody attached to magnetic beads are shown. (D) In order to identify unrelated proteins eluted from the c-Myc magnetic beads, a similar experiment was conducted with selected proteins but incubating only with the secondary antibody. A lane of SDS-PAGE stained with Bio-Safe Coomassie Stain corresponding to c-Myc magnetic beads alone eluted using Laemmli sample buffer was included (C--). The bands corresponding to fragments of the mouse anti-c-Myc antibody attached to magnetic beads are shown. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32046307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$TDP1 depletion sensitizes glioblastoma-resistant cancer cells to temozolomide. (a) Cell lysates from RKO and DLD1 cancer cell lines were fractionated by SDS–PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz), anti-Tubulin (Abcam) and anti-APE1 (Novus) antibodies (left). RKO and DLD1 cells were compared for their survival following exposure with the indicated doses of MMS for 15 min at 37°C (right). Data are the average of three independent experiments ± s.e.m. Where not visible, error bars are smaller than the symbol. (b) RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control RKO (RKOSc siRNA) and RKO cells in which TDP1 levels were depleted (RKOTDP1 siRNA) were examined for their survival following exposure to the indicated doses of MMS, as described earlier in the text (right). (c) Glioblastoma multiforme T98G and U87 cancer cell lines were analyzed for methylguanine methyltransferase (MGMT) expression using anti-MGMT antibodies (Abcam) (left). High-MGMT expressing T98G cells were compared with low-MGMT expressing U87 cells for their survival following exposure to increasing concentrations of the alkylating agent temozolomide (right). (d) TG98 cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control T98G cells (T98GSc siRNA) and cells in which TDP1 levels were depleted (TG98TDP1 siRNA) were incubated with DMSO or 150 μM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h followed by additional incubation with the indicated concentrations of MMS for 15 min at 37°C. Cell survival was blindly scored from three independent biological repeats, and data are the average ± s.e.m. (right). (e) Model for the repair of temozolomide-induced DNA breaks. Temozolomide delivers a methyl group to purine bases of DNA, resulting in O6-methyl guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a direct repair mechanism mediated by methylguanine methyltransferase (MGMT). Inherent and acquired resistance to temozolomide via MGMT expression presents a major challenge in cancer therapy, particularly for glioblastoma multiforme. TDP1 promotes the repair of methylated purines induced by temozolomide via a distinct non-canonical BER pathway. Increasing the load of unrepaired methylated purines by exploiting the limited availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical outcome of temozolomide-based cancer therapy. Asterisks denote statistical differences (P < 0.05; t-test) between control and TDP1-deficient cells. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24335147), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

OTULIN overexpression reduced the number of Iba-1+ microglial cells in the cortical ischemic penumbra in focal cerebral ischemia/reperfusion rats. A Representative images of Iba-1+ microglial cells that were morphologically classified into three types; scale bar = 10 μm. B Iba-1+ microglial cells in the ischemic penumbra and contralateral cortex of each group were detected by confocal immunofluorescence at 24 h, 72 h, and 7 days; scale bar = 75 μm. C The histogram represents the quantitative analysis of mean Iba-1 immunofluorescence intensity in each group (n = 6). Data are presented as the means ± SEMs; ###P < 0.001 versus the tMCAO group; &&&P < 0.001 versus the tMCAO+LV-Scramble group Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29544517), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FKBP51 modulates EMT hallmarks. (a and b) FKBP51 silencing of SAN melanoma cells decreases TGF-beta and T beta RIII expression. Normalized expression rates (mean±S.D.) of TGF-beta (a, left) and T beta RIII (b, left) mRNA levels; (a, n=3; b, n=5). FKBP51 siRNA-treated sample expression=1. Western blot assay of TGF-beta in SAN melanoma cells treated with nonsilencing (NS) RNA or FKBP51 siRNA (a, right). Flow cytometric analysis of T beta RIII (endoglin) expression (b, right): FKBP51 siRNA-treated cells moved to the left relative to NS RNA-treated cells because of reduced staining (MFI: 111±10 and 64±3 in NS RNA and FKBP51 siRNA-treated cells, respectively). (c, and d) FKBP51 overexpression enhances TGF-beta and T beta RIII expression. Normalized expression of TGF-beta (c, left) and T beta RIII (d, left) mRNA in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1. (c, n=3; d, n=5). Western blot assay of TGF-beta levels in the same cells (c, right). Anti-Flag-labelled exogenous FKBP51. Flow cytometric analysis of T beta RIII expression (d, right). FKBP51-overexpressing cells moved to the right relative to WT or EV cells, indicating increased expression. (e) Graphic representation of cell counts ( × 10−3) in WT, EV-, or FKBP51-stably transfected melanoma cell cultures. Results are means of six independent experiments each performed in triplicate. (f) FKBP51 upregulates colony number and size. Colonies were counted under low magnification ( × 10) at four points on each dish. The data represent the means of two independent experiments performed in triplicate. Magnification: upper, × 10; lower × 40. (g) Boyden chamber filters invaded by melanoma cells. Filter was stained with Crystal Violet. OD value was obtained by reading the eluted Crystal Violet with a spectrophotometer at a wavelength of 570 nm. The increased OD in FKBP51 samples indicated that FKBP51-overexpressing cells invaded matrigel more efficiently than control cells. The data represent the means of three independent experiments performed in triplicate Image collected and cropped by CiteAb from the following open publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Functional assessment of Fanconi anemia pathway. (a) The experimental scheme for MMC treatment. Twenty‐four hours after plating, cells were cultured with or without MMC 1 μM for an additional 24 hr, after which the cells were harvested for western blot or immunostaining. (b) Western blot with FANCD2 antibody of BJ, proband fibroblasts, FANCB mutant (null) fibroblasts and FANCD2 mutant (null) fibroblasts. (c) Western blot with FANCD2 antibody of non‐FA control lymphoblasts (LCL), proband LCL‐A‐2017, proband LCL‐B‐2017, FANCB mutant (null) LCL, and FANCD2 mutant (null) LCL. (d) Representative figures of FANCD2 foci formation in the indicated cells. (e) Quantification of FANCD2 foci formation following treatment with or without 1 μM MMC. Experiments were performed in triplicate. One hundred cells were counted for each experiment Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Pot1a prevents DDR in HSCs. a, b Telomeric DDR in 8 week-old LSK cells upon Pot1a knockdown. a Immunocytochemical staining of TRF1 (green) and 53BP1 (red). Foci co-stained with TRF1 and 53BP1 were identified as TIFs. Nuclei were stained with TOTO3 (blue). Scale bar, 2 μm. b Frequency of TIFs per cell after 1 week of culture. Data are expressed as the mean ± SD (n = 100, *p < 0.01 by t-test). Representative data from three independent experiments are shown. c–f Telomeric DDR in donor-derived control-GFP or Pot1a overexpressing 8 week-old LSK cells 4 months post BMT. c Immunocytochemical staining of TRF1 (green) and 53BP1 (red). Nuclei were stained with TOTO3 (blue). Scale bar, 2 μm. d Frequency of TIFs per cell. Data are expressed as the mean ± SD (n = 120, *p < 0.01 by t-test). Representative data from 3 independent experiments are shown. e Immunocytochemical staining of TRF1 (green) and RPA32 (red). f Immunocytochemical staining of TRF1 (green) and pChk1 (red). Scale bar, 2 μm. g Flow cytometric analysis of Chk1 and pChk1 in donor-derived GFP+ LSKCD48–CD150+ cells after 5 months of 2nd BMT. Mean fluorescence intensity of Chk1 and pChk1 (left panels). Data are expressed as the mean ± SD (n = 3, *p < 0.01 by t-test). Representative FACS profiles of Chk1 and pChk1 in donor-derived GFP+ LSKCD48–CD150+ cells (right panels) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28986560), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Lamin A/C-53BP1 interaction is regulated in a DNA damage-dependent manner. (A) Left; HDF were subjected to IR (10 Gy) and allowed to recover for 1 h. Association between A-type lamins and 53BP1 was assessed by immunoprecipitation of endogenous lamin A/C followed by immunoblotting with 53BP1 and lamin A/C antibodies. WCE, whole cell extract, IP: immunoprecipitates. WCE represents 5% input. Right; endogenous lamin A/C was immunoprecipitated and supernatants or pellets were analysed by immunoblotting for interaction with JMJD2A. (B) U2OS/GFP-lamin A cells were pretreated with caffeine (20 mm) for 1 h before exposure to IR (10 Gy, 1 h recovery). Cell extracts were then subjected to immunoprecipitation using GFP-Trap beads, and bound complexes were then analysed by immunoblotting using 53BP1 and GFP antibodies. WCE represents 1% input. (C) As in (C) except cells were pretreated with 10 μm ATMi for 1 h before IR. WCE represents 1% input. (D) U2OS/GFP-lamin A cells were subjected to laser micro-irradiation, fixed 1 h later and immunostained with gamma -H2AX antibody. Scale bar, 10 μm. (E) U2OS cells were transfected with siCTRL or siLMNA and subjected to laser micro-irradiation, fixed 15 min later and then processed for immunofluorescence with gamma -H2AX and 53BP1 antibodies. Scale bar, 10 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25645366), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Po, Bv, Ma, Pm, ChHa

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Bv, Ma, Pm, ChHa

Applications:

, , , , , , , , , , , , , ,

Applications: , , , , , , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-5031A

Alt Catalog# IMG-5031A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-27149AF350
Alexa Fluor 405	NBP2-27149AF405
Alexa Fluor 488	NBP2-27149AF488
Alexa Fluor 532	NBP2-27149AF532
Alexa Fluor 594	NBP2-27149AF594
Alexa Fluor 647	NBP2-27149AF647
Alexa Fluor 700	NBP2-27149AF700
Alexa Fluor 750	NBP2-27149AF750
Allophycocyanin	NBP2-27149APC
Allophycocyanin/Cy7	NB100-56566APCCY7
Biotin	NBP2-27149B
DyLight 350	NBP2-27149UV
DyLight 405	NBP2-27149V
DyLight 488	NBP2-27149G
DyLight 550	NBP2-27149R
DyLight 594	NB100-56566DL594
DyLight 650	NBP2-27149C
DyLight 680	NBP2-27149FR
DyLight 755	NBP2-27149IR
FITC	NBP2-27149F
HRP	NBP2-27149H
Janelia Fluor 549	NB100-56566JF549
Janelia Fluor 646	NB100-56566JF646
PE	NBP2-27149PE
PE/Atto594	NB100-56566PEATT594
PE/Cy5.5	NB100-56566PECY55
PE/Cy7	NB100-56566PECY7
PerCP	NBP2-27149PCP
mFluor Violet 450 SE	NBP2-27149MFV450
mFluor Violet 500 SE	NBP2-27149MFV500
mFluor Violet 610 SE	NBP2-27149MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-27149
BSA Free	NB100-56566SS
Azide Free	NBP2-27149SS

compare

(select up to 3 products from this page to compare)

NB100-56506

TRF-2 Antibody (4A794.15) - BSA Free

(1 Review)

(114 Publications)

0.1 mg

NB100-56506

Immunohistochemistry-Paraffin: TRF-2 Antibody (4A794.15) [NB100-56506] - Transitional cell carcinoma, urinary bladder, stained with TRF2 antibody (4 ug/mL), peroxidase-conjugate and DAB chromogen. Note specific nuclear staining. Tumor/normal adjacent tissue array slide was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.

Immunocytochemistry/Immunofluorescence: TRF-2 Antibody (4A794.15) [NB100-56506] - Localization of candidate RNAs at telomeres. Localization of SNORD17 at telomeres in human U-2 OS cells. Cells were fixed and sequentially incubated with Abs against TRF-2 and AlexaFluor 488-conjugated anti-mouse IgG. Subsequently, the cells were hybridized with the RNA probes and subjected to fluorescence microscopy. Three different cells are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0123387), licensed under a CC-BY license.

Flow Cytometry: TRF-2 Antibody (4A794.15) [NB100-56506] - Intracellular flow cytometric analysis of TRF2 in 10^6 human Jurkat cells using 0.1 ug of NB100-56506. The shaded histogram represents cells alone, blue represents isotype control and red represents NB100-56506, anti-TRF2.

Western Blot: TRF-2 Antibody (4A794.15) [NB100-56506] - Total protein from mouse 3T3 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-TRF2 in 1% non-fat milk in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: TRF-2 Antibody (4A794.15) [NB100-56506] - Localization of candidate RNAs at telomeres. Localization of NEAT1 at telomeres in human U-2 OS cells. Cells were fixed and sequentially incubated with Abs against TRF-2 and AlexaFluor 488-conjugated anti-mouse IgG. Subsequently, the cells were hybridized with the RNA probes and subjected to fluorescence microscopy. Three different cells are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0123387), licensed under a CC-BY license.

Flow Cytometry: TRF-2 Antibody (4A794.15) [NB100-56506] - An intracellular stain was performed on A431 cells with TRF2 Antibody [4A794.15] NB100-56506 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Immunocytochemistry/Immunofluorescence: TRF-2 Antibody (4A794.15) [NB100-56506] - Staining of TRF2-bound telomeres in human HeLa cells (Courtesy of Fotiadou, et al, 2004).

Immunocytochemistry/Immunofluorescence: TRF-2 Antibody (4A794.15) [NB100-56506] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-TRF-2 (4A794.15) conjugated to FITC [NB100-56506F] at 5 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

TRF2deltaBdeltaM expression induces chromosome end-to-end fusions in all inducible cell lines. (A) Immunoblots of MCF-10A, TO, SH-TO and SV-TO cell lines with and without DOX and HEK 293T. After 96 h of DOX treatment, the inducible cell lines expressed the truncated TRF2deltaBdeltaM protein (50 kDa); in contrast, uninduced cell lines, MCF-10A parental cell line and HEK 293T cells displayed only the endogen TRF2 protein (66 kDa). Lamin B1 was used as loading control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25502), licensed under a CC-BY licence.

HIF protein stabilization and HIF-1 alpha transcriptional activityRepresentative western blot showing protein levels of HIF-1 alpha and HIF-2 alpha (n = 3) in (A) cardiomyocytes derived from R1 and R1HIF-1 alpha −/− mESC exposed to 1% O2 and (B) cardiomyocytes derived from HG8 mESC exposed to 1% O2 and DMOG. Cropped representative western blots are shown from total of n = 3. mRNA levels of (C) Glut1 and (D) VEGF in cardiomyocytes derived from HG8 mESC exposed to 1% O2 or DMOG determined by qRT-PCR (n = 3). Data are presented as 2− delta Cq ± SEM (groups were compared using one-way ANOVA with the Tukey (HSD) post hoc test *p < 0.05). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29137374), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Acetaldehyde toxicity to human FANCD2‐deleted human cells and FANCD2 ubiquitylation in BRCA2‐deleted cellsA, BHuman DLD1 cells in which FANCD2 was deleted with CRISPR/Cas9 and control cells were incubated with the indicated concentrations of cisplatin (A) or acetaldehyde (B) for 6 days before processing for dose‐dependent viability assays. Graphs are representative of two independent experiments, each performed in triplicate. Error bars represent SD of triplicate values obtained from a single experiment. Inset, Western blot detection of FANCD2 expression. SMC1 was used as a loading control.CBRCA2‐proficient (+BRCA2) or BRCA2‐deficient (−BRCA2) DLD1 cells were incubated with 4 mM acetaldehyde for 48 h before being processed for immunoblotting as indicated.DH1299 cells expressing a DOX‐inducible BRCA2 shRNA were grown in the presence or absence of DOX and transfected with control or FANCD2 siRNA before being processed for immunoblotting as indicated. DOX, doxycycline. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28729482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

KDM4A interacts with the mTORC1/2 complex.(a) Relative mRNA levels of negative and positive regulators of the PTEN/AKT/mTOR pathway following KDM4A depletion. Quantifications of mRNAs by RT–qPCR were normalized against beta -actin (ActB) mRNA. Asterisks denote a statistical difference between siKDM4A-treated cells and siGFP control cells, two-sided t-test P<0.05 (graph represents two independent experiences). Error bars represent standard deviation. (b) Co-immunoprecipitation of endogenous mTORC1/2 complex members with Flag-KDM4A in 293T transfected cells. (c) Comparison of mTORC1/2-associated proteins with Flag-tagged mTOR or KDM4A. The 293T cells were transfected with either Flag-eYFP, Flag-KDM4A or Flag-mTOR, and protein lysates were subjected to anti-Flag immunoprecipitation. (d) Co-immunoprecipitation of Flag-KDM4A and HA-DEPTOR in 293T cells. (e) Endogenous KDM4A co-immunoprecipitates with Flag-DEPTOR. (f) DEPTOR PDZ domain associates with endogenous KDM4A. Flag immunoprecipitation of flag-tagged full length or fragments of DEPTOR. The samples were not sonicated in this experiment to confirm that the interaction is independent of nucleus disruption. (g) Endogenous KDM4A and DEPTOR associate in 293E cells. (h) Endogenous KDM4A and DEPTOR co-immunoprecipitate in NHA-hTERT cells. Image collected and cropped by CiteAb from the following open publication (//www.nature.com/articles/ncomms12700), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Ma, Mar

Species Glossary

Reactivity: Hu, Mu, Rt, Ma, Mar

Applications:

, , , , , , , , , ,

Applications: , , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-124A

Alt Catalog# IMG-124A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56506AF350
Alexa Fluor 405	NB100-56506AF405
Alexa Fluor 488	NB100-56506AF488
Alexa Fluor 532	NB100-56506AF532
Alexa Fluor 594	NB100-56506AF594
Alexa Fluor 647	NB100-56506AF647
Alexa Fluor 700	NB100-56506AF700
Alexa Fluor 750	NB100-56506AF750
Allophycocyanin	NB100-56506APC
Biotin	NB100-56506B
DyLight 350	NB100-56506UV
DyLight 405	NB100-56506V
DyLight 488	NB100-56506G
DyLight 550	NB100-56506R
DyLight 594	NB100-56506DL594
DyLight 650	NB100-56506C
DyLight 680	NB100-56506FR
DyLight 755	NB100-56506IR
FITC	NB100-56506F
HRP	NB100-56506H
Janelia Fluor 549	NB100-56506JF549
Janelia Fluor 646	NB100-56506JF646
PE	NB100-56506PE
PerCP	NB100-56506PCP
mFluor Violet 450 SE	NB100-56506MFV450
mFluor Violet 500 SE	NB100-56506MFV500
mFluor Violet 610 SE	NB100-56506MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-56506SS
Azide Free	NBP2-33212

compare

(select up to 3 products from this page to compare)

NBP2-24875

TLR3 Antibody (40C1285.6) - BSA Free

(87 Publications)

0.1 mg

NBP2-24875

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Mouse colon using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. Intense signal was found in subset of cells at the bases of the crypts.

Flow Cytometry: TLR3 Antibody (40C1285.6) [NBP2-24875] - Expression of TLR3 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR3 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR3. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.

Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in lysates from A) human intestine and F) ovary using TLR3 antibody at 3 ug/ml. Goat anti-mouse HRP conjugate was used as secondary.

Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - HEK293T cells were transfected with TLR3, TLR3-9-3 and TLR3-3-9. Western blot was performed using anti-TLR3 or anti-HA antibodies. Anti-Beta-actin antibodies were used as a loading control. The representative data from three experiments are shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092391) licensed under a CC-BY license.

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Tissue section of mouse intestine using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. The representative image shows a punctate staining of the ER and endosomes in a subset of cells in Peyer's patches (organized lymphoid nodules) in the tested section.

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in (A) human gut lumen (longitudinal section, transverse region) using this antibody at 10 ug/ml (Data courtesy Dr. Elizabeth Furrie, University of Dundee) and mouse spleen tissue using isotype control (B) and this antibody (C) at 5 mg/ml.

NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. (A) T-47D, MCF-7, Bcap37, MDA-MB-231 and SK-BR-3 cells were collected for the extraction of proteins and analysed for N-myc downstream-regulated gene 2 (NDRG2) expression by immunoblotting. (B) SK-BR-3 cells with low NDRG2 expression were infected by an adenovirus carrying NDRG2 (Ad-NDRG2) or negative control LacZ (Ad-LacZ), and T-47D cells with high NDRG2 were transfected with small interfering RNA targeting NDRG2 (NDRG2 siRNA) or negative control siRNA (Con siRNA). Thereafter proteins were extracted from these cells and analysed by immunoblotting. beta -actin was used as a loading control. Before being cultured in 25 mM high-glucose (H.G.) or 5.5 mM low-glucose (L.G.) medium, SK-BR-3 cells were infected by Ad-NDRG2 (C) and T-47D cells were transfected by NDRG2 siRNA (D). Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for 1 to 5 days. (C) and (D) The data presented are means ± SD for three independent experiments; error bars represent SD from 8 replicative wells. (C) *P < 0.05 and **P < 0.01 versus H.G. Ad-LacZ. #P < 0.05 versus L.G. Ad-LacZ. (D) *P < 0.05 versus H.G. Con siRNA. (E) and (F) SK-BR-3 cells were cultured to glucose medium at concentrations of 0, 5, 25, 50 and 100 mM for 24 hours, and then the protein or mRNA was extracted for analysis by immunoblotting (E) or real-time PCR (F). beta -actin was used as a loading control. The data presented are means ± SD; error bars represented SD from 3 replicative wells. *P < 0.05 and **P < 0.01 versus control group. (G) SK-BR-3 or (H) T-47D cells, respectively, were infected with Ad-NDRG2 or transfected NDRG2 siRNA and cultured in a high-glucose medium (25 mM) for 48 hours. Next, cell glucose concentrations were measured. (G) and (H) The data presented are means ± SD of three independent experiments; error bars represent SD from 8 replicative wells. *P < 0.05 and **P < 0.01 versus control group. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Characterization of selected mutant protein glycosylation status or localization.(A) Two independent, representative experiments to analyze the glycosylation status of GFP-NPC1 wild type and GFP-NPC1 P251C/L929C, as determined by immunoblot of indicated samples with anti-GFP antibodies after 6% SDS PAGE; samples were incubated at 70°C in SDS PAGE sample buffer for 10 min prior to loading. Molecular weight markers are shown at left in kilodaltons here and in all subsequent gels shown. (B), Localization of NPC1 P251/L929C/P249K/P259K in NPC1−/− HeLa cells as in Figure 1C. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32410728), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Notch-1 is identified as an intermediate molecule in the miR-1956-VEGF axis. (A) Notch-1 is a target gene for miR-1956. The sequence of miR-1956, the potential binding site at the 3' UTR of Notch-1 mRNA, and the nucleotides mutated in the Notch-1-3' UTR mutant are shown. HEK293 cells were transiently cotransfected with miR-1956 mimic or NC using luciferase reporter vectors. The luciferase activity was normalized to the activity of Renilla luciferase. Data are shown as mean ± SD from three independent experiments. *, significantly different from NC; **, p < 0.01. After transfection with 50 nmol/L of miR-1956 mimic for 3 days, the mRNA level of Notch-1 was determined using qRT-PCR (B), and the protein expression of Notch-1 was measured using western blotting (C). For B, data are shown as mean ± SD from three independent experiments. *, significantly different from control; **, p < 0.01. For C, representative images of two independent experiments are shown. Data are shown as mean ± SD. *, significantly different from control; **, p < 0.01. ADMSCs were transfected with 2.5 μg Notch-1 plasmid and 50 nmol/L miR-1956 mimic or 100 nmol/L miR-1956 inhibitor for 3 days, the intracellular expression of Notch-1 (D) and VEGF (E) was detected by western blotting. For D and E, representative images of four independent experiments are shown. Data are shown as mean ± SD. *, significantly different from the control group transfected with control plasmid and NC mimic or inhibitor; *, p < 0.01; **, p < 0.01. #, significantly different from the group transfected with Notch-1 plasmid and NC mimic or inhibitor; #, p < 0.05. One-way ANOVA followed by Tukey's post-test was performed (A-E). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31938051), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Ca

Species Glossary

Reactivity: Hu, Mu, Ca

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-315A

Alt Catalog# IMG-315A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24875AF350
Alexa Fluor 405	NBP2-24875AF405
Alexa Fluor 488	NBP2-24875AF488
Alexa Fluor 532	NBP2-24875AF532
Alexa Fluor 594	NBP2-24875AF594
Alexa Fluor 647	NBP2-24875AF647
Alexa Fluor 700	NBP2-24875AF700
Alexa Fluor 750	NBP2-24875AF750
Allophycocyanin	NBP2-24875APC
Biotin	NBP2-24875B
Biotin	NBP2-24782
DyLight 350	NBP2-24875UV
DyLight 405	NBP2-24875V
DyLight 488	NBP2-24875G
DyLight 550	NBP2-24875R
DyLight 594	NBP2-24875DL594
DyLight 650	NBP2-24875C
DyLight 680	NBP2-24875FR
DyLight 755	NBP2-24875IR
FITC	NBP2-24875F
HRP	NBP2-24875H
Janelia Fluor 549	NBP2-24875JF549
Janelia Fluor 646	NBP2-24875JF646
PE	NBP2-24902
PE	NBP2-24875PE
PerCP	NBP2-24875PCP
mFluor Violet 450 SE	NBP2-24875MFV450
mFluor Violet 500 SE	NBP2-24875MFV500
mFluor Violet 610 SE	NBP2-24875MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP2-24875SS
Azide Free	NBP2-33263

compare

(select up to 3 products from this page to compare)

NB100-56704

IKK alpha Antibody (14A231) - BSA Free

(83 Publications)

0.1 mg

NB100-56704

Flow Cytometry: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - An intracellular stain was performed on Hek293 cells with IKK alpha Antibody (14A231) NB100-56704 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Total protein from various Human, Mouse and Rat cell lines were separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/mL anti-IKK-alpha in 1% non-fat milk in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). An antibody dilution of 1:10 was used. Image objective 40X.

Immunohistochemistry: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - B-I. Immunohistochemistry showing the expression of the transgenic protein in N-IKKa and C-IKKa tumors. Staining with NB100-56704 antibody is shown. (B, C) Representative images showing the expression of transgenic IKKa in tumors and adjacent skin of N-IKKa/TgAC mice (B), and C-IKKa/TgAC animals (C). (D, E) Detail showing the nuclear (D) or cytoplasmic (E) localization of the transgenic IKKa in tumors. (F, G) Similar levels of expression of the transgenic IKKa in different N-IKKa tumors. By contrast variable levels of expression of the transgene are observed between different C-IKKa tumors (H, I). t: tumor; s: non-tumoral skin. Scale bar: (B, C) 100um; (D, E) 80 um; (F-I) 200 um. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/8792/text/) licensed under a CC-BY license.

Western Blot: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Analysis of IKK alpha in Daudi cell lysate using IKK alpha antibody at 1 ug/mL.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - A431 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-IKK alpha Antibody (14A231) at 2 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunocytochemistry/Immunofluorescence: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-IKK alpha Antibody (14A231) at 2 ug/mL overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunohistochemistry-Paraffin: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Analysis of a FFPE tissue section of human kidney using 1:200 dilution of IKK alpha clone 14A231 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

Immunohistochemistry-Paraffin: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - Expression of the transgenic IKK alpha protein in skin of C-IKK alpha and N-IKK alpha mice. D-E. Expression of exogenous IKK alpha protein in back skin of 1-month-old mice. Immunostaining with the NB100-56704 anti-IKK alpha antibody is shown. Note the cytoplasmic expression of the transgene in the C-IKK alpha mice (D). By contrast, it is located in the nuclei of cells in the N-IKK alpha mice (E). In both types of transgenic mice the exogenous IKK alpha is expressed in basal keratinocytes (bk), in the outer root sheath of hair follicles (ORS) and in cells surrounding the sebaceous glands (sb). Scale bar: 60um. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/8792/text/) licensed under a CC-BY license.

Simple Western: IKK alpha Antibody (14A231) - BSA Free [NB100-56704] - IKK alpha Antibody (14A231) [NB100-56704] - Image shows a specific band for IKK alpha in 0.5 mg/mL of Daudi (left) and U937 (right) lysate. This exeriment was performed under reducing conditions using the 12-230 kDa separation system.

NEMO-Ub binding is essential for TNFalpha signaling, but not for IL-1beta signaling.(a) Schematic illustration of NEMO deletions or point mutations. (b,c) Effects of NEMO C-terminal deletion mutants on TNFalpha and IL-1beta signaling. NEMO-/Y MEFs were reconstituted with mock, NEMO WT or different C-terminal deletion constructs and stimulated with TNFalpha (b) or IL-1beta (c). Effects on NF-kappaB signaling were investigated by determining IkappaBalpha phosphorylation and degradation in Western Blots as well as NF-kappaB-DNA binding by EMSA. (d,e) Effects of NEMO D311N on TNFalpha and IL-1beta signaling. NEMO-/Y MEFs were reconstituted with mock, NEMO WT or NEMO D311N point mutant and stimulated with TNFalpha (d) or IL-1beta (e). Analysis on NF-kappaB signaling were performed as in (b,c). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26740240), licensed under a CC-BY licence.

Treatments with dASOs resulted in significant lower viable tumor volume(A) Total tumor volumes at the end of treatment (day 15). NOD-SCID mice with established PC-3 subcutaneous xenografts were treated with control, 6w2 and 6w5 dASOs for 15 consecutive days and tumors were harvested at the end of treatment. Dash line refers to mean tumor volumes at day 0 (before treatment, 78 mm3). (B) Percentage of tumor necrosis at harvest determined by H&E staining. (C) Percentage of viable tumour growth from day 0 to day 15 of treatment. Viable tumour volume refers to tumor without necrotic regions (Materials and Methods). Error bars indicate mean ± S.E.M. (D) BIRC6 IHC staining intensity of tumors of control ASO-6w2- and 6w5-treated groups at the end of treatment. (E) Percentage of Ki-67 positive cells as determined by IHC of 6w2- and 6w5-treated tumors at harvest. (F) Representative images of control ASO-6w2- and 6w5-treated PC-3 xenografts using H&E, and IHC staining of BIRC6, cleaved-caspase 3 and Ki-67. 20x magnification. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25071009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Pm

Species Glossary

Reactivity: Hu, Mu, Rt, Pm

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-136A

Alt Catalog# IMG-136A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-27409AF350
Alexa Fluor 405	NBP2-27409AF405
Alexa Fluor 488	NBP2-27409AF488
Alexa Fluor 532	NBP2-27409AF532
Alexa Fluor 594	NBP2-27409AF594
Alexa Fluor 647	NBP2-27409AF647
Alexa Fluor 700	NBP2-27409AF700
Alexa Fluor 750	NBP2-27409AF750
Allophycocyanin	NBP2-27409APC
Biotin	NBP2-27409B
DyLight 350	NBP2-27409UV
DyLight 405	NBP2-27409V
DyLight 488	NBP2-27409G
DyLight 550	NBP2-27409R
DyLight 594	NB100-56704DL594
DyLight 650	NBP2-27409C
DyLight 680	NBP2-27409FR
DyLight 755	NBP2-27409IR
FITC	NBP2-27409F
HRP	NBP2-27409H
Janelia Fluor 549	NBP2-27409JF549
Janelia Fluor 646	NBP2-27409JF646
PE	NBP2-27409PE
PerCP	NBP2-27409PCP
mFluor Violet 450 SE	NBP2-27409MFV450
mFluor Violet 500 SE	NBP2-27409MFV500
mFluor Violet 610 SE	NBP2-27409MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-27409
BSA Free	NB100-56704SS

compare

(select up to 3 products from this page to compare)

NBP2-24906

TLR7 Antibody - BSA Free

(4 Reviews)

(78 Publications)

0.1 mg

NBP2-24906

Immunocytochemistry/Immunofluorescence: TLR7 Antibody [NBP2-24906] - Immunolocalization of TLR7 (A) and glial fibrillary acidic protein (GFAP) (B) in murine myenteric plexus. Most of the GFAP positive cells were also positive for TLR7 in the merged image (C, yellow staining). (Courtesy of Barajon I, et al., Journal of Histochemistry and Cytochemistry, 57(11): 1013-;1023, 2009.)

Immunohistochemistry: TLR7 Antibody [NBP2-24906] - Expression of the TLRs 5 and 7 were evaluated in the PDAC tissue by their staining intensity using TLR5 antibody (NBP2-24787) and TLR7 antibody (NBP2-24906). Note negative staining in E and G; positive staining in F and H. For TLR7 immunopositivity was detectable in the cytoplasm with no notable membranous or nuclear positivity. TLR5 showed distinctive nuclear positivity, and detectable positivity in the cytoplasm in some samples. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0219245) licensed under a CC-BY license.

Immunohistochemistry-Frozen: TLR7 Antibody [NBP2-24906] - analysis of frozen mouse ear skin tissue using anti-TLR7 antibody. Image from verified customer review.

Immunohistochemistry-Frozen: TLR7 Antibody [NBP2-24906] - analysis of TLR7 in acetone-fixed, frozen mouse ear skin section using anti-TLR7 antibody. Image from verified customer review.

Western Blot: TLR7 Antibody [NBP2-24906] - Analysis using the Azide Free version of NBP2-24906. Detection of TLR7 in RAW cell lysate using this antibody.

Immunocytochemistry/Immunofluorescence: TLR7 Antibody [NBP2-24906] - Analysis using the Azide Free version of NBP2-24906. Staining of Raw 246.7 cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). Image objective 40x. An antibody dilution of 1:10 was used.

Immunohistochemistry-Paraffin: TLR7 Antibody - BSA Free [NBP2-24906] - Analysis of a FFPE tissue section of human skin using 1:200 dilution of TLR7 antibody (NBP2-24906). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

Expression of TLR7 in lung tissues of non-smokers, smokers, and COPD patients. Total protein and mRNA were obtained from lung tissues of non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15). (E) Representative immunohistochemistry images are shown. The control IgG isotype showed negative staining. Data are presented as individual values and mean +/- standard deviation. Exact P values were obtained using Kruskal-Wallis and Dunn's post-hoc tests. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-015-0179-5), licensed under a CC-BY licence.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Alt Catalog#

IMG-581A

Alt Catalog# IMG-581A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24906AF350
Alexa Fluor 405	NBP2-24906AF405
Alexa Fluor 488	NBP2-24906AF488
Alexa Fluor 532	NBP2-24906AF532
Alexa Fluor 594	NBP2-24906AF594
Alexa Fluor 647	NBP2-24906AF647
Alexa Fluor 700	NBP2-24906AF700
Alexa Fluor 750	NBP2-24906AF750
Allophycocyanin	NBP2-24906APC
Biotin	NBP2-24906B
DyLight 350	NBP2-24906UV
DyLight 405	NBP2-24906V
DyLight 488	NBP2-24906G
DyLight 550	NBP2-24906R
DyLight 594	NBP2-24906DL594
DyLight 650	NBP2-24906C
DyLight 680	NBP2-24906FR
DyLight 755	NBP2-24906IR
FITC	NBP2-24777
HRP	NBP2-24906H
Janelia Fluor 549	NBP2-24906JF549
Janelia Fluor 646	NBP2-24906JF646
PE	NBP2-24906PE
PE	NBP2-31071
PerCP	NBP2-24906PCP
mFluor Violet 450 SE	NBP2-24906MFV450
mFluor Violet 500 SE	NBP2-24906MFV500
mFluor Violet 610 SE	NBP2-24906MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-24905
Azide Free	NBP2-24905SS
BSA Free	NBP2-24906SS

compare

(select up to 3 products from this page to compare)

NBP3-07012

Noxa Antibody (114C307.1R) - BSA Free

(72 Publications)

0.1 mg

NBP3-07012

Flow Cytometry: Noxa Antibody (114C307.1R) [NBP3-07012] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1R] NBP3-07012 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Noxa Antibody (114C307.1R) NBP3-07012 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , ,

Applications: , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB600-1159AF350
Alexa Fluor 405	NB600-1159AF405
Alexa Fluor 488	NB600-1159AF488
Alexa Fluor 532	NB600-1159AF532
Alexa Fluor 594	NB600-1159AF594
Alexa Fluor 647	NB600-1159AF647
Alexa Fluor 700	NB600-1159AF700
Alexa Fluor 750	NB600-1159AF750
Biotin	NB600-1159B
Biotin	NBP2-24790
DyLight 350	NB600-1159UV
DyLight 405	NB600-1159V
DyLight 488	NB600-1159G
DyLight 550	NB600-1159R
DyLight 594	NB600-1159DL594
DyLight 650	NB600-1159C
DyLight 680	NB600-1159FR
DyLight 755	NB600-1159IR
FITC	NB600-1159F
HRP	NB600-1159H
Janelia Fluor 549	NB600-1159JF549
Janelia Fluor 646	NB600-1159JF646
mFluor Violet 450 SE	NB600-1159MFV450
mFluor Violet 500 SE	NB600-1159MFV500
mFluor Violet 610 SE	NB600-1159MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Non-Recombinant Monoclonal	NB600-1159SS
Azide Free	NBP2-33250
Non-Recombinant Monoclonal	NB600-1159
BSA Free	NBP3-07012SS

compare

(select up to 3 products from this page to compare)

NB100-56722

TLR2 Antibody (TL2.1) - BSA Free

(64 Publications)

0.1 mg

NB100-56722

Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).

Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.

Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.

Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.

Reactivity:

Hu, Mu, Rt, Ca, Rb

Species Glossary

Reactivity: Hu, Mu, Rt, Ca, Rb

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-416A

Alt Catalog# IMG-416A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56722AF350
Alexa Fluor 405	NB100-56722AF405
Alexa Fluor 488	NB100-56722AF488
Alexa Fluor 532	NB100-56722AF532
Alexa Fluor 594	NB100-56722AF594
Alexa Fluor 647	NB100-56722AF647
Alexa Fluor 700	NB100-56722AF700
Alexa Fluor 750	NB100-56722AF750
Allophycocyanin	NB100-56722APC
Biotin	NB100-56722B
DyLight 594	NB100-56722DL594
FITC	NB100-56722F
Janelia Fluor 549	NB100-56722JF549
Janelia Fluor 646	NB100-56722JF646
PE	NBP2-24909
PE	NB100-56722PE
mFluor Violet 450 SE	NB100-56722MFV450
mFluor Violet 500 SE	NB100-56722MFV500
mFluor Violet 610 SE	NB100-56722MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NB100-56726
BSA Free	NB100-56722SS
Azide Free	NB100-56726SS

compare

(select up to 3 products from this page to compare)

NBP2-24737

p73 Antibody (5B429) - BSA Free

(60 Publications)

0.1 mg

NBP2-24737

$Western Blot: p73 Antibody (5B429) [NBP2-24737] - Consequences of DHX9 knockdown on protein levels of p53 targets in HCT116 p53+/+ and p53-/- cells. Western blot analysis of p53 transcriptional targets in HCT116 p53+/+ and p53-/- cells. Cells were harvested 6 days post-transduction and extracts were fractionated on 8% SDS-PAGE gels. All probings were performed on the same blot. Actin and eEF2 are used as loading controls. Quantitation of intensity levels of the proteins in the shDHX9 samples relative to the shFLuc. 1309 samples are indicated beneath each band. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/15889/text/), licensed under a CC-BY license.$

Immunohistochemistry-Paraffin: p73 Antibody (5B429) [NBP2-24737] - FFPE breast cancer probed with p73 antibody at 5 ug/ml. Human tissue was used for this test. Staining of tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.

Western Blot: p73 Antibody (5B429) [NBP2-24737] - Analysis of p73 in A) transfected cell lysate and B) HeLa cell lysate at 2 ug/ml.

Flow (Intracellular): p73 Antibody (5B429) [NBP2-24737] - An intracellular stain was performed on HeLa cells with pan p73 (5B429) antibody NBP2-24737 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).

Simple Western: p73 Antibody (5B429) [NBP2-24737] - Lane view shows a specific band for p73 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.

Activation of FANCD2 monoubiquitination following treatment with the EZH2 inhibitor EPZ-6438(A-C) MCF10A (A), HCT116 p53+/+ and p53-/- (B), and U2OS (C) cells were treated with the indicated concentrations of the EZH2-specific inhibitor EPZ-6438 for 24 h (A and B) or 24, 48, and 72 h (C). Whole-cell lysates were prepared and immunoblotted with the indicated antibodies. L.E., light exposure; D.E., dark exposure; L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, relative band intensity. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29100324), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-246

Alt Catalog# IMG-246

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24737AF350
Alexa Fluor 405	NBP2-24737AF405
Alexa Fluor 488	NBP2-24737AF488
Alexa Fluor 532	NBP2-24737AF532
Alexa Fluor 594	NBP2-24737AF594
Alexa Fluor 647	NBP2-24737AF647
Alexa Fluor 700	NBP2-24737AF700
Alexa Fluor 750	NBP2-24737AF750
Allophycocyanin	NBP2-24737APC
Biotin	NBP2-24737B
DyLight 350	NBP2-24737UV
DyLight 405	NBP2-24737V
DyLight 488	NBP2-24737G
DyLight 550	NBP2-24737R
DyLight 594	NBP2-24737DL594
DyLight 650	NBP2-24737C
DyLight 680	NBP2-24737FR
DyLight 755	NBP2-24737IR
FITC	NBP2-24737F
HRP	NBP2-24737H
Janelia Fluor 549	NBP2-24737JF549
Janelia Fluor 646	NBP2-24737JF646
PE	NBP2-24737PE
mFluor Violet 450 SE	NBP2-24737MFV450
mFluor Violet 500 SE	NBP2-24737MFV500
mFluor Violet 610 SE	NBP2-24737MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP2-24737SS
Azide Free	NBP2-33259

compare

(select up to 3 products from this page to compare)

NB100-56559

S100A7/Psoriasin Antibody (47C1068) - BSA Free

(1 Review)

(50 Publications)

0.1 mg

NB100-56559

Immunocytochemistry/Immunofluorescence: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - S100A7/psoriasin detection was performed on (A) untreated and (B) LPS-treated (100 ng/mL, 21 hrs) HOPE-fixed NCI-H727 cells using the monoclonal Psoriasin/HID5/S100A7 antibody (NB100-56559). (C) Positive control is shown by the expression of the nuclear Ki67 antigen with the MIB-1 (2 ug/mL) antibody. (D) Negative control was included omitting the primary antibody.

Immunohistochemistry: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Inhibition of KDM expression in vivo. Skin biopsies from normal control skin (Cont) or lesional psoriatic skin (Pso) were collected. Skin sections were stained with Hematoxylin and immunodetection of cytokeratin 10, loricrin, filaggrin, involucrin and S100A7 was performed. Scale bar 100 um. Results are from one experiment representative of three. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0101937), licensed under a CC-BY license.

Flow (Intracellular): S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - An intracellular stain was performed on Jurkat cells with S100A7/Psoriasin antibody (47C1068) NBP2-24911PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.. Using the PE format of this antibody.

Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Staining of human skin. FFPE tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/mL.

Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Tissue section of human esophageal squamous cell carcinoma (SCC) using 5 ug/mL concentration of Psoriasin/S100A7 antibody (clone 47C1068). Diffused to granular cytoplasmic immunostaining was observed all over the tissue section with highest expression levels in the areas with cancer cells especially in the developing squamous keratin pearls.

Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis of FFPE tissue section of human lymph node cancer using 5 ug/mL concentration of Psoriasin/S100A7 antibody (clone 47C1068). Very strong cytoplasmic immunopositivity of Psoriasin/S100A7 protein was observed in the cancer cells.

Immunohistochemistry-Paraffin: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Human breast tissue stained with psoriasin antibody at 1:200 using peroxidase-conjugate and DAB chromogen. Antigen retrieval with citrate buffer, pH 6.

Simple Western: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Image shows a specific band for S100A7/Psoriasin in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Simple Western: S100A7/Psoriasin Antibody (47C1068) [NB100-56559] - Analysis using Azide Free version of NB100-56559. Image shows a specific band for Psoriasin/S100A7 in 0.05 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

S100A7 activated p53 related anti-proliferative pathways. (A) Log2 fold change of mRNA expression of p53 pathway factors after S100A7 overexpression. (B) WB of p53 and S100A7 in MCF7-p53-CKD transfected with S100A7 or vector control. p53 shRNA transcription and p53 knockdown in MCF7-p53-CKD was induced by Doxycyclin (Dox). (C) S100A7 activated p53, ATR, chk-1, chk-2 in MCF7 cells.

PINK1 translation is critical for the accumulation of PINK1 upon mitochondrial damage. aPINK1 mRNA levels were not altered by mitochondrial damage. HeLa cells were incubated with 10 μM CCCP or combination of 10 μM oligomycin and 4 μM antimycin for 2 h and then, PINK1 mRNA levels were measured by qRT-PCR. PINK1 mRNA level was normalized to the corresponding GAPDH levels and quantified as a percentage of control (n = 8, t-test). b, c Translation is involved in PINK1 accumulation upon CCCP treatment. HeLa cells were first pre-incubated with 100 μM cycloheximide (CHX) for 2 h and then washed. Cells were further incubated with 10 μM CCCP with or without CHX for 2 h (n = 4, two-way ANOVA). Values are mean ± SEM (n.s. = non-significant, ***p < 0.001) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/27456084), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu

Species Glossary

Reactivity: Hu, Mu

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-409A

Alt Catalog# IMG-409A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56559AF350
Alexa Fluor 405	NBP2-24911AF405
Alexa Fluor 488	NBP2-24911AF488
Alexa Fluor 532	NB100-56559AF532
Alexa Fluor 594	NB100-56559AF594
Alexa Fluor 647	NBP2-24911AF647
Alexa Fluor 700	NBP2-24911AF700
Alexa Fluor 750	NB100-56559AF750
Allophycocyanin	NBP2-24911APC
Biotin	NBP2-24911B
DyLight 350	NBP2-24911UV
DyLight 405	NBP2-24911V
DyLight 488	NBP2-24911G
DyLight 550	NBP2-24911R
DyLight 594	NB100-56559DL594
DyLight 650	NBP2-24911C
DyLight 680	NBP2-24911FR
DyLight 755	NBP2-24911IR
FITC	NBP2-24911F
HRP	NBP2-24911H
Janelia Fluor 549	NB100-56559JF549
Janelia Fluor 646	NB100-56559JF646
PE	NBP2-24911PE

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-24911
BSA Free	NB100-56559SS

compare

(select up to 3 products from this page to compare)

NB100-56505

Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

(44 Publications)

0.1 mg

NB100-56505

Immunocytochemistry/Immunofluorescence: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - MG-63 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Osteoprotegerin (98A1071) at 5 ug/ml overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Flow Cytometry: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Intracellular staining of 10^6 HeLa cells using 0.2 ug of OPG antibody, 0.5 ul of PE secondary.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Human breast tissue stained with OPG antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Staining of human liver. Tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Staining of human heart tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.

Reactivity:

Hu, Mu, Rt, Rb

Species Glossary

Reactivity: Hu, Mu, Rt, Rb

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-103A

Alt Catalog# IMG-103A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56505AF350
Alexa Fluor 405	NB100-56505AF405
Alexa Fluor 488	NB100-56505AF488
Alexa Fluor 532	NB100-56505AF532
Alexa Fluor 594	NB100-56505AF594
Alexa Fluor 647	NB100-56505AF647
Alexa Fluor 700	NB100-56505AF700
Alexa Fluor 750	NB100-56505AF750
Allophycocyanin	NB100-56505APC
Allophycocyanin/Cy7	NB100-56505APCCY7
Biotin	NB100-56505B
DyLight 350	NB100-56505UV
DyLight 405	NB100-56505V
DyLight 488	NB100-56505G
DyLight 550	NB100-56505R
DyLight 594	NB100-56505DL594
DyLight 650	NB100-56505C
DyLight 680	NB100-56505FR
DyLight 755	NB100-56505IR
FITC	NB100-56505F
HRP	NB100-56505H
Janelia Fluor 549	NB100-56505JF549
Janelia Fluor 646	NB100-56505JF646
PE	NB100-56505PE
PE/Atto594	NB100-56505PEATT594
PE/Cy5.5	NB100-56505PECY55
PE/Cy7	NB100-56505PECY7
PerCP	NB100-56505PCP
mFluor Violet 450 SE	NB100-56505MFV450
mFluor Violet 500 SE	NB100-56505MFV500
mFluor Violet 610 SE	NB100-56505MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB100-56505SS
Azide Free	NBP2-33211

compare

(select up to 3 products from this page to compare)

NB100-56618

TRAILR2/TNFRSF10B Antibody

(1 Review)

(42 Publications)

0.1 mg

NB100-56618

<b>Biological Strategies Validation. </b>Immunohistochemistry: TRAILR2/TNFRSF10B Antibody [NB100-56618] - Pharmacodynamic assays for ONC201. IHC analyses of CHOP, TRAILR2/TNFRSF10B, and double-stranded DNA breaks (TUNEL) in baseline and ONC201-treated biopsies for an endometrial cancer patient. The biopsy was done 9.8 months after starting ONC201 treatment (7 days after the most recent ONC201 dose). Image collected and cropped by CiteAb from the following publication (//jitc.biomedcentral.com/articles/10.1186/s40425-019-0599-8) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: TRAIL R2/TNFRSF10B Antibody [NB100-56618] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-TRAIL R2 (H76) at 5ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Western Blot: TRAILR2/TNFRSF10B Antibody [NB100-56618] - TRAIL R2/TNFRSF10B Antibody [NB100-56618] - Analysis using the Azide Free version of NB100-56618. Detection of 20 ug of whole cell lysates from HL60 cells with anti-TRAIL-R2 at 5 ug/ml.

Pharmacodynamic assays for ONC201. d) IHC analyses of CHOP, DR5, and double-stranded DNA breaks (TUNEL) in baseline and ONC201-treated biopsies for an endometrial cancer patient. The biopsy was done 9.8 months after starting ONC201 treatment (7 days after the most recent ONC201 dose). Each error bar indicates SEM Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31118108), licensed under a CC-BY licence.

Reactivity:

Hu, Mu

Species Glossary

Reactivity: Hu, Mu

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Alt Catalog#

IMG-120A

Alt Catalog# IMG-120A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Validated by:

Validated by:

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NB100-55744

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Antibody Validation

Reviews

Host

Available Conjugates

Format

Marker

Modification

Clonality

Clone

Gene Symbol

Images Type

Isotype

Preservative

Research Areas

Has Sample Size

Promotional Item

Species Glossary

TLR9 Antibody (26C593.2) - BSA Free

TLR4 Antibody (76B357.1) - BSA Free

TRF-2 Antibody (4A794.15) - BSA Free

TLR3 Antibody (40C1285.6) - BSA Free

IKK alpha Antibody (14A231) - BSA Free

TLR7 Antibody - BSA Free

Noxa Antibody (114C307.1R) - BSA Free

TLR2 Antibody (TL2.1) - BSA Free

p73 Antibody (5B429) - BSA Free

S100A7/Psoriasin Antibody (47C1068) - BSA Free

Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

TRAILR2/TNFRSF10B Antibody